Saturday 17 October 2026
Export MSLE’s income statement to Excel — free account
Satellos Bioscience Inc.
MSLE Healthcare Biotechnology
In the quarter to June 2026, EPS fell 42.5% and free cash flow fell 65.7%, each against the same quarter a year earlier.
6.46
0.38
−5.56%
Follow MSLE
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (70.45%) | (50.74%) | (66.37%) | (89.74%) |
+8 more TTM periods Free account |
|
| (64.76%) | (47.66%) | (60.20%) | (79.73%) | ||
ROIC |
0.00% | (2,495.26%) | (22,347.13%) | 0.00% | |
Return on Tangible Assets |
(57.77%) | (40.33%) | (89.52%) | (64.78%) | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(1.39) | (1.40) | (1.62) | (1.55) | |
Free Cash Flow |
(29.01) | (25.82) | (23.60) | (21.56) | |
Capital Expenditures |
(0.01) | (0.01) | (0.01) | (0.01) | |
| Other line items | |||||
Cash ROIC |
(23.83%) | (18.37%) | (42.53%) | (31.42%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.01 | 0.01 | 0.01 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.84 | 0.91 | 0.95 | 0.98 | |
Depreciation/Fixed assets |
0.71 | 0.50 | 0.80 | 2.17 | |
Capex/Depreciation |
(1.40) | (2.50) | (1.50) | (0.46) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(1.39) | (1.40) | (1.62) | (1.55) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates